Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Source : https://pubmed.ncbi.nlm.nih.gov/38587249/
In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis...
Each dose of olezarsen also significantly reduced the levels of APOC3, apolipoprotein B, and non-HDL cholesterol, with no significant change in the LDL cholesterol level.
Share
Associations of Dietary Cholesterol Consumption With Incident Diabetes and Cardiovascular Disease: the Role of Genetic Variability in Cholesterol Absorption and Disease Predisposition
OBJECTIVE. Whether genetic susceptibility to disease and dietary cholesterol (DC) absorption contribute to inconsistent associations of DC consumption with
Dietary cholesterol consumption was not associated with incident diabetes and CVD in the overall sample and in subgroups stratified by genetic predisposition to cholesterol absorption and the diseases.
Share
Failure of Lipid Control by PCSK9 Inhibitors in Compound Heterozygous Familial Hypercholesterolemia Complicated With Premature Myocardial Infarction: a Case Report
Source : https://pubmed.ncbi.nlm.nih.gov/38487640/
Familial hypercholesterolemia (FH) is a serious autosomal dominant disorder. Managing blood lipids in FH patients poses greater challenges for clinicians. Drug therapy may not always yield satisfactory results, particularly in...
The inefficacy of proprotein-converting enzymes/kexin 9 inhibitors may arise from the extensive mutations, leading to loss of low-density lipoprotein receptor activity.
Share
The estimated treatment difference between NNC0385-0434 100 mg and evolocumab 140 mg was 3.4%.
Share
An Inclisiran First Strategy vs Usual Care in Patients With Atherosclerosis
Source : https://pubmed.ncbi.nlm.nih.gov/38593947/
An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns.
The "inclisiran first" strategy led to significantly greater reductions in LDL-C from baseline to day 330 versus usual care.
Share